Aspirin and Preeclampsia
This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy
| Condition(s) | Preeclampsia Postpartum |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients. |
| Who can participate | Inclusion Criteria: 1. Pregnant Adults between 18 and 45 years of age 2. Diagnosed with preeclampsia 3. Presenting for delivery with a singleton gestation. Exclusion Criteria: 1. We will exclude patients in labor 2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation 3. Plan to deliver outside of the participating site 4. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI. 5. Aspirin allergy 6. Clear indication for aspirin therapy or contraindication to aspirin therapy 7. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestina |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Lead sponsor | University of Chicago |
| Locations | Chicago, Illinois, United States |
| Start date | 2021-02-15 |
| NCT ID | NCT04479072 |
| Official listing | https://clinicaltrials.gov/study/NCT04479072 |